{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT05702229",
      "orgStudyIdInfo": {
        "id": "D7986C00001"
      },
      "secondaryIdInfos": [
        {
          "id": "2022-002840-29",
          "type": "EUDRACT_NUMBER"
        }
      ],
      "organization": {
        "fullName": "AstraZeneca",
        "class": "INDUSTRY"
      },
      "briefTitle": "Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma",
      "officialTitle": "An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma"
    },
    "statusModule": {
      "statusVerifiedDate": "2025-11",
      "overallStatus": "RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2023-01-16",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2026-07-03",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2027-09-28",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2022-12-07",
      "studyFirstSubmitQcDate": "2023-01-18",
      "studyFirstPostDateStruct": {
        "date": "2023-01-27",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2025-11-14",
      "lastUpdatePostDateStruct": {
        "date": "2025-11-17",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "AstraZeneca",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.",
      "detailedDescription": "Approximately 240 participants will be assigned across 6 substudies, with approximately 40 evaluable participants of the confirmed recommend dose by SRC for study intervention in each corresponding substudy."
    },
    "conditionsModule": {
      "conditions": [
        "Gastric Cancer"
      ],
      "keywords": [
        "Locally advanced",
        "Metatstatic",
        "Gastric adenocarcinoma",
        "GEJ adenocarcinoma",
        "GEMINI-Gastric"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 240,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Substudy 1",
          "type": "EXPERIMENTAL",
          "description": "Volrustomig plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)",
          "interventionNames": [
            "Drug: Volrustomig",
            "Drug: FOLFOX",
            "Drug: XELOX"
          ]
        },
        {
          "label": "Substudy 2",
          "type": "EXPERIMENTAL",
          "description": "Rilvegostomig plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)",
          "interventionNames": [
            "Drug: Rilvegostomig",
            "Drug: FOLFOX",
            "Drug: XELOX"
          ]
        },
        {
          "label": "Substudy 3",
          "type": "EXPERIMENTAL",
          "description": "AZD0901 plus volrustomig and 5-fluorouracil or capecitabine",
          "interventionNames": [
            "Drug: Volrustomig",
            "Drug: AZD0901",
            "Drug: 5-Fluorouracil",
            "Drug: Capecitabine"
          ]
        },
        {
          "label": "Substudy 4",
          "type": "EXPERIMENTAL",
          "description": "AZD0901 plus rilvegostomig and 5-fluorouracil or capecitabine",
          "interventionNames": [
            "Drug: Rilvegostomig",
            "Drug: AZD0901",
            "Drug: 5-Fluorouracil",
            "Drug: Capecitabine"
          ]
        },
        {
          "label": "Substudy 5",
          "type": "EXPERIMENTAL",
          "description": "AZD7789 plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)",
          "interventionNames": [
            "Drug: FOLFOX",
            "Drug: XELOX",
            "Drug: AZD7789"
          ]
        },
        {
          "label": "Substudy 6",
          "type": "EXPERIMENTAL",
          "description": "AZD0901 plus AZD7789 and 5-fluorouracil or capecitabine",
          "interventionNames": [
            "Drug: AZD7789",
            "Drug: AZD0901",
            "Drug: 5-Fluorouracil",
            "Drug: Capecitabine"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Rilvegostomig",
          "description": "an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion",
          "armGroupLabels": [
            "Substudy 2",
            "Substudy 4"
          ]
        },
        {
          "type": "DRUG",
          "name": "Volrustomig",
          "description": "an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion",
          "armGroupLabels": [
            "Substudy 1",
            "Substudy 3"
          ]
        },
        {
          "type": "DRUG",
          "name": "FOLFOX",
          "description": "5-fluorouracil 400 mg/m\\^2 IV, oxaliplatin 85 mg/m\\^2, leucovorin 400 mg/m\\^2 (or levoleucovorin 200 mg/m\\^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m\\^2 IV 24 h day 1-2",
          "armGroupLabels": [
            "Substudy 1",
            "Substudy 2",
            "Substudy 5"
          ]
        },
        {
          "type": "DRUG",
          "name": "XELOX",
          "description": "capecitabine 1000 mg/m\\^2 BID, days 1 to 14, oxaliplatin 130 mg/m\\^2, day 1",
          "armGroupLabels": [
            "Substudy 1",
            "Substudy 2",
            "Substudy 5"
          ]
        },
        {
          "type": "DRUG",
          "name": "AZD7789",
          "description": "an anti PD 1 and anti TIM 3 bispecific antibody; IV infusion",
          "armGroupLabels": [
            "Substudy 5",
            "Substudy 6"
          ]
        },
        {
          "type": "DRUG",
          "name": "AZD0901",
          "description": "an anti Claudin18.2 ADC; IV infusion",
          "armGroupLabels": [
            "Substudy 3",
            "Substudy 4",
            "Substudy 6"
          ]
        },
        {
          "type": "DRUG",
          "name": "5-Fluorouracil",
          "description": "5-FU, IV infusion, Q3W",
          "armGroupLabels": [
            "Substudy 3",
            "Substudy 4",
            "Substudy 6"
          ]
        },
        {
          "type": "DRUG",
          "name": "Capecitabine",
          "description": "Oral take, Q3W",
          "armGroupLabels": [
            "Substudy 3",
            "Substudy 4",
            "Substudy 6"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "ORR (per RECIST 1.1 as assessed by Investigator)",
          "description": "the proportion of participants who have a confirmed complete response or confirmed partial response, as determined by the Investigator at local site per RECIST 1.1.",
          "timeFrame": "Through substudy completion, an average of 2 years"
        },
        {
          "measure": "PFS6 (per RECIST 1.1 as assessed by Investigator)",
          "description": "the proportion of participants alive and progression-free at 6 months.",
          "timeFrame": "Through substudy completion, an average of 2 years"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "PFS per RECIST 1.1 as assessed by the Investigator",
          "description": "the time from the start of study intervention until progression per RECIST 1.1 as assessed by the Investigator at the local site or death due to any cause in the absence of progression.",
          "timeFrame": "Through substudy completion, an average of 2 years"
        },
        {
          "measure": "OS",
          "description": "the time from the start of study intervention until the date of death due to any cause.",
          "timeFrame": "Through substudy completion, an average of 2 years"
        },
        {
          "measure": "other safety related endpoints",
          "description": "Incidence of AEs, AESIs, and SAEs.",
          "timeFrame": "Through substudy completion, an average of 2 years"
        },
        {
          "measure": "DoR per RECIST 1.1 based on Investigator assessment.",
          "description": "the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 by the Investigator at local site or death due to any cause in the absence of disease progression.",
          "timeFrame": "Through substudy completion, an average of 2 years"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years or older at the time of signing the ICF.\n* Body weight \\> 35 kg.\n* Previously untreated for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.\n* Has measurable target disease assessed by the Investigator based on RECIST 1.1.\n* ECOG PS zero or one.\n* Life expectancy of at least 12 weeks.\n* Adequate organ and bone marrow function.\n* Has central lab confirmed Claudin18.2 status at screening from archival tumour collected within past 24 months or from a fresh biopsy when Substudy 3, Substudy 4 or Substudy 6 is open for recruitment.\n\nExclusion Criteria:\n\n* Participants with HER2-positive (3+ by IHC, or 2+ by IHC and positive by in situhybridisation) or indeterminate gastric or GEJ carcinoma.\n* Untreated or progressive CNS metastatic disease, any leptomeningeal disease, or cord compression.\n* Participants with ascites which cannot be controlled with appropriate interventions.\n* Active infectious diseases, including tuberculosis, HIV infection, or hepatitis A/B/C.\n* Uncontrolled intercurrent illness.\n* Active or prior documented autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment.\n* History of another primary malignancy.\n* Previous treatment with an immune-oncology agent.\n* Previous treatment with any modalities of Claudin18.2 target therapy or MMAE exposure (when Substudy 3, Substudy 4, or Substudy 6 is open for recruitment).",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "centralContacts": [
        {
          "name": "AstraZeneca Clinical Study Information Center",
          "role": "CONTACT",
          "phone": "1-877-240-9479",
          "email": "information.center@astrazeneca.com"
        }
      ],
      "locations": [
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Los Angeles",
          "state": "California",
          "zip": "90017",
          "country": "United States",
          "geoPoint": {
            "lat": 34.05223,
            "lon": -118.24368
          }
        },
        {
          "facility": "Research Site",
          "status": "WITHDRAWN",
          "city": "Los Angeles",
          "state": "California",
          "zip": "90095",
          "country": "United States",
          "geoPoint": {
            "lat": 34.05223,
            "lon": -118.24368
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Baton Rouge",
          "state": "Louisiana",
          "zip": "70817",
          "country": "United States",
          "geoPoint": {
            "lat": 30.44332,
            "lon": -91.18747
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Grand Rapids",
          "state": "Michigan",
          "zip": "49503",
          "country": "United States",
          "geoPoint": {
            "lat": 42.96336,
            "lon": -85.66809
          }
        },
        {
          "facility": "Research Site",
          "status": "WITHDRAWN",
          "city": "New Hyde Park",
          "state": "New York",
          "zip": "11042",
          "country": "United States",
          "geoPoint": {
            "lat": 40.7351,
            "lon": -73.68791
          }
        },
        {
          "facility": "Research Site",
          "status": "WITHDRAWN",
          "city": "New York",
          "state": "New York",
          "zip": "10028",
          "country": "United States",
          "geoPoint": {
            "lat": 40.71427,
            "lon": -74.00597
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "New York",
          "state": "New York",
          "zip": "10065",
          "country": "United States",
          "geoPoint": {
            "lat": 40.71427,
            "lon": -74.00597
          }
        },
        {
          "facility": "Research Site",
          "status": "WITHDRAWN",
          "city": "New York",
          "state": "New York",
          "zip": "11210",
          "country": "United States",
          "geoPoint": {
            "lat": 40.71427,
            "lon": -74.00597
          }
        },
        {
          "facility": "Research Site",
          "status": "WITHDRAWN",
          "city": "Shirley",
          "state": "New York",
          "zip": "11967",
          "country": "United States",
          "geoPoint": {
            "lat": 40.80149,
            "lon": -72.8676
          }
        },
        {
          "facility": "Research Site",
          "status": "WITHDRAWN",
          "city": "The Bronx",
          "state": "New York",
          "zip": "10469",
          "country": "United States",
          "geoPoint": {
            "lat": 40.84985,
            "lon": -73.86641
          }
        },
        {
          "facility": "Research Site",
          "status": "WITHDRAWN",
          "city": "Pittsburgh",
          "state": "Pennsylvania",
          "zip": "15212",
          "country": "United States",
          "geoPoint": {
            "lat": 40.44062,
            "lon": -79.99589
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Beijing",
          "zip": "100142",
          "country": "China",
          "geoPoint": {
            "lat": 39.9075,
            "lon": 116.39723
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Hangzhou",
          "zip": "310003",
          "country": "China",
          "geoPoint": {
            "lat": 30.29365,
            "lon": 120.16142
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Hangzhou",
          "zip": "310020",
          "country": "China",
          "geoPoint": {
            "lat": 30.29365,
            "lon": 120.16142
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Harbin",
          "zip": "150081",
          "country": "China",
          "geoPoint": {
            "lat": 45.75,
            "lon": 126.65
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Hefei",
          "zip": "230031",
          "country": "China",
          "geoPoint": {
            "lat": 31.86389,
            "lon": 117.28083
          }
        },
        {
          "facility": "Research Site",
          "status": "COMPLETED",
          "city": "Kunming",
          "zip": "650118",
          "country": "China",
          "geoPoint": {
            "lat": 25.03889,
            "lon": 102.71833
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Wuhan",
          "zip": "430079",
          "country": "China",
          "geoPoint": {
            "lat": 30.58333,
            "lon": 114.26667
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Yinchuan",
          "zip": "750004",
          "country": "China",
          "geoPoint": {
            "lat": 38.46806,
            "lon": 106.27306
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Zhengzhou",
          "zip": "450052",
          "country": "China",
          "geoPoint": {
            "lat": 34.75778,
            "lon": 113.64861
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Chūōku",
          "zip": "104-0045",
          "country": "Japan",
          "geoPoint": {
            "lat": 33.63867,
            "lon": 130.67068
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Kashiwa",
          "zip": "227-8577",
          "country": "Japan",
          "geoPoint": {
            "lat": 35.86224,
            "lon": 139.97732
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Sunto-gun",
          "zip": "411-8777",
          "country": "Japan"
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Seoul",
          "zip": "03080",
          "country": "South Korea",
          "geoPoint": {
            "lat": 37.566,
            "lon": 126.9784
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Seoul",
          "zip": "03722",
          "country": "South Korea",
          "geoPoint": {
            "lat": 37.566,
            "lon": 126.9784
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Seoul",
          "zip": "05505",
          "country": "South Korea",
          "geoPoint": {
            "lat": 37.566,
            "lon": 126.9784
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Seoul",
          "zip": "06351",
          "country": "South Korea",
          "geoPoint": {
            "lat": 37.566,
            "lon": 126.9784
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Barcelona",
          "zip": "08035",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Elche(Alicante)",
          "zip": "03202",
          "country": "Spain",
          "geoPoint": {
            "lat": 38.26218,
            "lon": -0.70107
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "L'Hospitalet de Llobregat",
          "zip": "08908",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.35967,
            "lon": 2.10028
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Madrid",
          "zip": "28007",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Madrid",
          "zip": "28040",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Santander",
          "zip": "39008",
          "country": "Spain",
          "geoPoint": {
            "lat": 43.46589,
            "lon": -3.80493
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Hsinchu",
          "zip": "300",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 24.80361,
            "lon": 120.96861
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Kaohsiung City",
          "zip": "80756",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 22.61626,
            "lon": 120.31333
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Taichung",
          "zip": "404",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 24.1469,
            "lon": 120.6839
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Tainan",
          "zip": "70403",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 22.99083,
            "lon": 120.21333
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Taipei",
          "zip": "10002",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 25.05306,
            "lon": 121.52639
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Taipei",
          "zip": "11259",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 25.05306,
            "lon": 121.52639
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Taoyuan District",
          "zip": "333",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 24.9896,
            "lon": 121.3187
          }
        },
        {
          "facility": "Research Site",
          "status": "WITHDRAWN",
          "city": "Edinburgh",
          "zip": "EH4 2XU",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 55.95206,
            "lon": -3.19648
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Leeds",
          "zip": "LS9 7TF",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 53.79648,
            "lon": -1.54785
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "London",
          "zip": "EC1M 6BQ",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 51.50853,
            "lon": -0.12574
          }
        },
        {
          "facility": "Research Site",
          "status": "RECRUITING",
          "city": "Oxford",
          "zip": "OX3 7LE",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 51.75222,
            "lon": -1.25596
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "YES",
      "description": "Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.\n\nAll request will be evaluated as per the AZ disclosure commitment:\n\nhttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.\n\nYes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.",
      "timeFrame": "AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",
      "accessCriteria": "When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",
      "url": "https://astrazenecagroup-dt.pharmacm.com/DT/Home"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-13"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D013274",
          "term": "Stomach Neoplasms"
        }
      ],
      "ancestors": [
        {
          "id": "D005770",
          "term": "Gastrointestinal Neoplasms"
        },
        {
          "id": "D004067",
          "term": "Digestive System Neoplasms"
        },
        {
          "id": "D009371",
          "term": "Neoplasms by Site"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D004066",
          "term": "Digestive System Diseases"
        },
        {
          "id": "D005767",
          "term": "Gastrointestinal Diseases"
        },
        {
          "id": "D013272",
          "term": "Stomach Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C410216",
          "term": "Folfox protocol"
        },
        {
          "id": "C519688",
          "term": "XELOX"
        },
        {
          "id": "D005472",
          "term": "Fluorouracil"
        },
        {
          "id": "D000069287",
          "term": "Capecitabine"
        }
      ],
      "ancestors": [
        {
          "id": "D014498",
          "term": "Uracil"
        },
        {
          "id": "D011744",
          "term": "Pyrimidinones"
        },
        {
          "id": "D011743",
          "term": "Pyrimidines"
        },
        {
          "id": "D006573",
          "term": "Heterocyclic Compounds, 1-Ring"
        },
        {
          "id": "D006571",
          "term": "Heterocyclic Compounds"
        },
        {
          "id": "D003841",
          "term": "Deoxycytidine"
        },
        {
          "id": "D003562",
          "term": "Cytidine"
        },
        {
          "id": "D011741",
          "term": "Pyrimidine Nucleosides"
        },
        {
          "id": "D003853",
          "term": "Deoxyribonucleosides"
        },
        {
          "id": "D009705",
          "term": "Nucleosides"
        },
        {
          "id": "D009706",
          "term": "Nucleic Acids, Nucleotides, and Nucleosides"
        }
      ]
    }
  },
  "hasResults": false
}